Vildagliptin: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
Newer edit →
David Canner (talk | contribs)
7,699 edits
New page: <applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Vildagliptin, better known as ____, ([[___]])"/> ===Better Known as: === * Marketed By: * Maj...
 
David Canner (talk | contribs)
7,699 edits
No edit summary
Line 1: Line 1:
<applet  load="" size="480" color="" frame="true"  spin="on" Scene ="" align="right" caption="Vildagliptin, better known as ____, ([[___]])"/>
<applet  load="" size="480" color="" frame="true"  spin="on" Scene ="" align="right" caption="Vildagliptin, better known as Galvus, ([[___]])"/>
===Better Known as: ===
===Better Known as: Galvus===
* Marketed By:
* Marketed By:
* Major Indication:
* Major Indication:

Revision as of 12:33, 13 December 2010

Vildagliptin, better known as Galvus, ([[___]])

Drag the structure with the mouse to rotate

Better Known as: Galvus

  • Marketed By:
  • Major Indication:
  • Drug Class:
  • Date of FDA Approval (Patent Expiration):
  • 2009 Sales:
  • Importance:
  • See Pharmaceutical Drugs for more information about other drugs and diseases.

Mechanism of Action

Pharmacokinetics

DPP4 Inhibitor Pharmacokinetics
Parameter Vildagliptin
(Galvus) 		Sitagliptin
(Januvia) 		Saxagliptin
(Onglyza)
Tmax (hr) 1.75 1-4 2
Cmax (ng/ml) 290 330 34
Bioavailability (%) 85 87 67
Protein Binding (%) 9 38 0
T1/2 (hr) 2-3 12.4 2.5
AUC (ng/ml/hr) 1610 3470 101
IC50 (nM) 3 18 50
Renal Clearance (L/h) 13.0 21.0 13.8
Volume Distribution (L) 71 198 151
Dosage (mg) 100 100 5
Metabolism Hydrolysis Hepatic (CYP3A4 & CYP2C8) Hepatic (CYP3A4)

For Pharmacokinetic Data References, see: References

References


Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

David Canner
Retrieved from "https://proteopedia.openfox.io/wiki/index.php?title=Vildagliptin&oldid=1156031"